![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide once weekly for the](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide once weekly for the
Description
14% in SURMOUNT-2, and up to 92% vs
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide once weekly for the](https://www.thelancet.com/cms/asset/9fea4172-4531-416b-9ac5-29b8135a69eb/gr1.jpg)
This dual approach explains why Tirzepatide shows better tolerability profiles than its single-receptor competitors
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide once weekly for the](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b8/13093900/dae8e400456b/EDM2-9-e70225-g003.jpg)
A prescriber may write a prescription in Units or in mLs
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide once weekly for the](https://dgnvxbcc3-res.cloudinary.com/image/upload/v1773004536/Journals/Automation/AFP/2024/0800/p199-ut1-gif.gif)
Gastrointestinal adverse effects represent another important concern
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide once weekly for the](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=725936156423519)
Self-pay options are commonly available
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide once weekly for the](https://floridaweightlossmd.com/wp-content/uploads/2026/01/Tirzepatide-before-and-after-weight-loss-results-and-timelines-in-2026-1024x683.jpg)
The immune system responds with mild inflammation the same natural process that causes redness after a bug bite or scratch
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide once weekly for the](https://onlinelibrary.wiley.com/cms/asset/4917a99d-8d3b-4fcc-9113-f9df11d9fc8f/oby.v31.1.cover.jpg)
